Selank

What it is

Selank is a synthetic heptapeptide developed in Russian peptide research programs. PubChem lists Selank as threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline, with related Selank acetate records also present^{[1 –2 ]}. In public peptide markets it is usually sold as a nasal or injectable “anxiolytic” or “nootropic” peptide.

Chemical structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and molecular formula C33H57N11O9^{[1 ]}. It is commonly described as a stabilized analog related to tuftsin biology and has been studied mainly in Russian neuropsychopharmacology literature for anxiety-related indications^{[9 –10 ]}.

Mechanism

The peptide is often described as a tuftsin analog. Tuftsin is an immunologically active tetrapeptide fragment, and Selank extends a tuftsin-like sequence with a Pro-Gly-Pro motif intended to affect stability and biologic activity. This background explains why Selank research often mixes neuropsychiatric, immune, and molecular signaling themes^{[9 –10 ]}.

Clinical literature exists, but it is narrow and largely Russian-language. A randomized study compared Selank with medazepam in patients with generalized anxiety disorder and neurasthenia^{[9 ]}. Reviews describe molecular effects relevant to anxiety biology, but the evidence base is not equivalent to FDA approval or broad modern replication^{[10 ]}.

When sold online, Selank is commonly presented for anxiety, stress tolerance, mood, focus, cognition, or social anxiety. No FDA-approved Selank product exists, and there is no approved route, dose, indication, contraindication profile, drug-interaction framework, or long-term safety label in the United States^{[3 –7 ]}.

Regulatory status

Selank is not FDA-approved for any indication. No FDA-approved prescription product containing Selank was identified in FDA approval materials reviewed for this draft^{[3 –7 ]}.

503A and 503B status

FDA’s current 503A and 503B compounding pages state that bulk drug substances must satisfy specific statutory conditions to be used in compounding^{[3 ,5 ]}. Selank was not identified on the April 22, 2026 503A category PDF or the reviewed 503B category/list materials^{[4 –6 ]}. It was also not identified on the 503A or 503B bulks lists reviewed for this draft^{[3 ,5 –6 ]}.

FDA safety-risk listing

FDA’s safety-risk page lists “Selank acetate (TP-7)” among withdrawn nominated substances and states that compounded drugs containing selank acetate may pose immunogenicity risk for certain routes of administration due to aggregation and peptide-related impurities^{[7 ]}. FDA further states that it lacks important information regarding safety issues raised by selank acetate administered to humans^{[7 ]}.

Conservative classification

Because Selank is not FDA-approved and was not identified on current bulks lists, this draft uses the conservative classification that it is not available through routine FDA-compliant prescription or compounding channels in the United States. Selank was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed for this draft^{[8 ]}.

Date of last regulatory verification: May 5, 2026.

Research summary

The main human clinical citation located for this draft is a Russian randomized controlled trial by Zozulia and colleagues^{[9 ]}. The study included 62 patients with generalized anxiety disorder and neurasthenia and compared Selank in 30 patients with medazepam in 32 patients^{[9 ]}. The PubMed abstract states that the study evaluated efficacy and possible mechanisms of action^{[9 ]}. Because the article is in Russian, the full methods, blinding, endpoint definitions, and adverse-event details should be reviewed by a Russian-speaking medical reviewer before making stronger claims.

Mechanistic reviews

Vyunova and colleagues reviewed molecular aspects of Selank’s biological activity and described peptide-based anxiolytic research in relation to limitations of conventional GABAergic anxiolytics^{[10 ]}. Reviews of this kind are useful for mechanism, but they do not establish approval-quality efficacy.

Mechanistic research has discussed Selank in relation to monoamine systems, gene expression, immune signaling, and endogenous regulatory peptides^{[10 ]}. These mechanisms remain exploratory. They should not be translated into claims that Selank treats anxiety disorders, depression, ADHD, PTSD, social anxiety, cognitive decline, or stress-related illness in humans.

Where the evidence ends

No large, multicenter, independently replicated, FDA-style randomized trial was identified for Selank as of 2026-05-05. No FDA-reviewed safety database or label was identified. Therefore, the quality of evidence should be described as limited, regional, and preliminary.

Overall, Selank has more human clinical literature than many gray-market peptides, but the evidence is concentrated in Russian-language publications and does not establish a current lawful US medical use.

Public discourse

The FDA human drug compounding safety-risk page summarized withdrawn Selank acetate nomination concerns^{[7 ]}.

Tatiana V. Vyunova and colleagues, Russian peptide researchers, reviewed Selank as a peptide anxiolytic research compound^{[10 ]}.

A. A. Zozulia and colleagues, Russian clinical researchers, compared Selank with medazepam in generalized anxiety disorder and neurasthenia^{[9 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Selank has no FDA-approved prescribing information. There is therefore no FDA-reviewed label establishing contraindications, common adverse reactions, pregnancy or lactation safety, drug interactions, carcinogenicity data, or monitoring recommendations^{[3 –7 ]}.

Compounding-related risks

FDA’s compounding safety concerns include immunogenicity risk for certain routes of administration due to aggregation and peptide-related impurities^{[7 ]}. FDA also states that it lacks important safety information for selank acetate administered to humans^{[7 ]}.

Theoretical concerns

Theoretical concerns include sedation, paradoxical anxiety, interactions with benzodiazepines, antidepressants, stimulants, alcohol, or other psychoactive drugs, and use in people with bipolar disorder, psychosis, seizure disorders, pregnancy, or complex psychiatric comorbidity. These concerns are not quantified in FDA labeling because no FDA label exists.

Published Russian clinical literature may contain safety observations, but those data were not sufficient for FDA approval and should be reviewed in full before using them for patient-facing safety statements^{[9 –10 ]}.

Long-term safety data are insufficient. Products sold online as Selank may also raise identity, sterility, concentration, impurity, and route-of-administration concerns.

Available through

Selank is not currently available through routine FDA-compliant prescription or compounding channels in the United States as of 2026-05-05^{[3 –7 ]}. It is not FDA-approved and was not identified on the FDA 503A or 503B bulks lists reviewed for this draft.

ProPeptideGuide does not link to or endorse grey-market vendors, research-chemical sellers, imported products, online peptide shops, or clinics advertising Selank for anxiety, stress, focus, mood, cognition, or performance use.